Can cholesterol rise after switching to Inclisiran?

Yes—indirect evidence suggests LDL Cholesterol rose about 16% after a switch from evolocumab to Inclisiran. The article reviews Inclisiran, a prescription injection used to lower cholesterol. It draws on ORION-3, a study involving people who switched from evolocumab. Evolocumab is another cholesterol-lowering injection. The excerpt does not give the size or age range of this group. The main takeaway is that steady lowering does not always mean stronger lowering. The article describes consistent drops in LDL Cholesterol with Inclisiran. It reports greater lowering and less variation than Ezetimibe, a cholesterol-lowering pill, used alone. But the switch from evolocumab was linked to a modest rise of about 16%. That figure needs context. It comes from indirect evidence, not a direct comparison designed to test which drug works better. It also does not mean cholesterol returned to its untreated level. The excerpt gives no starting or final blood levels for the switch. So it cannot show how close people were to their own targets. For BioSocial members, this makes before-and-after bloodwork especially useful when comparing treatment experiences. A record can include the result before a switch, later results, and test dates. Notes on injection dates and other medication changes can add context. Sharing those details helps the community compare more than a single percentage. The reported 16% rise is a finding to discuss, not a forecast for everyone. What changes have you seen in your LDL Cholesterol numbers after starting or switching to Inclisiran?